GLP-1 Evidence

Sigurnost

GLP-1 nuspojave, rangirane po učestalosti

Gastrointestinalne nuspojave su gotovo univerzalne i obično su pod kontrolom. Rijetki događaji koji dominiraju izvještavanjem su zaista rijetki.

Ažurirano 3 min čitanja 27 citati Snaga dokaza 4/5

Pogled odozgo na bolnički krevet i ormarić u zajedničkoj bolničkoj sobi
玄史生 · CC0 · Wikimedia Commons

Uobičajene nuspojave

Gotovo sve česte nuspojave su gastrointestinalne, a gotovo sve direktno proizlaze iz odgođenog pražnjenja želuca. Kroz programe ispitivanja obrazac je dosljedan [5][6][8]:

Tipični frekvencijski opsezi iz randomiziranih ispitivanja
UčinakOtprilike koliko je čestObrazac
MučninaVrlo česta (trećina do polovina)Dostiže vrhunac nakon svake doze, zatim se smiruje
ProljevČestiČesto rano, obično prolazan
ZatvorČestiMože trajati; često je to dugoročna i iritantna nuspojava
PovraćanjeČestiSnažno povezano s dozom
Bolovi u trbuhu, refluks, podrigivanjeČestiObično blagi
Reakcije na mjestu injekcijeRijetkeBlage
Prekid zbog nuspojavaNekoliko postoViše pri višim dozama

Razlika između "trećine ljudi se osjeća bolesno" i "nekoliko posto prestaje" je najkorisniji broj ovdje. Većina ljudi koji dožive mučninu to izdrži, obično zato što se stanje poboljšava.

Rijetke nuspojave o kojima se ljudi brinu

Pankreatitis, bolest žučne kese, tumori C-stanica štitne žlijezde i gastropareza dominiraju online raspravama daleko iznad njihove učestalosti u podacima.

  • Bolest žučne kese. Zaista povećana, ali to je u velikoj mjeri posljedica brzog gubitka težine, a ne direktne toksičnosti lijeka — brzi gubitak težine bilo kojim sredstvom povećava rizik od žučnih kamenaca.
  • Pankreatitis. Pomno se prati kroz cijelu klasu. Velike meta-analize ispitivanja kardiovaskularnih i bubrežnih ishoda nisu proizvele signal koji su raniji izvještaji slučajeva sugerirali [1].
  • Tumori C-stanica štitne žlijezde. Upozorenje dolazi iz studija na glodarima. To se nije prenijelo u demonstrirani ljudski signal, ali je razlog zašto su lijekovi kontraindicirani kod lične ili porodične istorije medularnog karcinoma štitne žlijezde ili MEN2.
  • Gastropareza. Odgođeno pražnjenje želuca je namjeravani mehanizam, kako je objašnjeno na stranici o mehanizmu. Teška trajna gastropareza je drugačija i mnogo rjeđa pojava.

Odsustvo značajnih signala sigurnosti u objedinjeni podacima ispitivanja

Kako izgledaju noviji oralni agensi

Oralni agonisti malih molekula su sada prošli kroz velika randomizirana ispitivanja u pretilosti i ranoj dijabetesu tipa 2 [2][3][4]. Njihov profil podnošljivosti izgleda kao kod injekcija — dominiraju iste gastrointestinalne nuspojave, s istom strategijom povećanja doze. Biti tableta ne mijenja mehanizam, a samim tim ne mijenja ni nuspojave. Više o oralnim opcijama.

Gdje se podaci iz ispitivanja i stvarni život razlikuju

Populacije u ispitivanjima su pregledane, nadgledane i povećane prema protokolu. Pregled iz 2025. godine o stvarnoj upotrebi i efikasnosti pokazao je da se široka slika sigurnosti održava izvan ispitivanja, ali s više varijabilnosti — uzrokovano bržim povećanjem, prekidima doze, prazninama u opskrbi i složenim proizvodima neizvjesnog sadržaja [9]. Većina najgorih ishoda prijavljenih izvan ispitivanja uključuje neprepisane izvore umjesto samih lijekova.

Bijele filmom obložene tablete u blister pakovanju
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Česta pitanja

Da li mučnina ikada potpuno nestaje?
Za većinu ljudi se smiruje unutar nekoliko sedmica nakon određene doze, i kratko se vraća pri svakom povećanju. Zatvor je učinak koji najvjerovatnije traje.
Da li je gubitak kose nuspojava?
Gubitak kose je dobro poznata posljedica brzog gubitka težine uopšte — telogena efuzija — a ne specifična toksičnost lijeka. Obično je privremen.
Trebam li prestati prije operacije?
Pitajte svog anesteziologa. Postoje specifične perioperativne smjernice jer želudac možda neće biti prazan nakon standardnog posta.
Da li nuspojave znače da lijek djeluje?
Ne. Mučnina i gubitak težine su oba povezana s dozom, ali pojedinci se u velikoj mjeri razlikuju u oba slučaja. Mnogi ljudi gube mnogo težine bez mnogo mučnine.
Dokazi iza ove stranice Stog grafikon koji prikazuje sastav 12 publikacija citiranih na ovoj stranici prema vrsti studije. 1911meta-analysis (1)randomised trial (9)review (1)other (1)
9 publikacija, 2018–2025. Ovdje su prisutna ispitivanja, ali malo sinteze, tako da pojedinačni rezultati još uvijek imaju veliku težinu i mogu se mijenjati. Izvor: vlastita lista citata ove stranice, ispod.

Reference

Svaka citacija u nastavku povezuje na izvorni recenzirani zapis na PubMed-u ili putem DOI-a. Ništa ovdje nije zamjena za medicinski savjet.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  4. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  5. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  7. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  8. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Cummings JL, Atri A, Sano M, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41865758
  9. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, et al. · The lancet. Diabetes & endocrinology · 2026 · Randomised controlled trial DOIPubMed 42251859
  10. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544435
  12. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  13. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Randomised controlled trial DOIPubMed 38095657Full text
  14. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  15. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37351564
  17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Inagaki N, Takeuchi M, Oura T, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35914543
  19. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  21. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Thomas MK, Nikooienejad A, Bray R, et al. · The Journal of clinical endocrinology and metabolism · 2021 · Randomised controlled trial DOIPubMed 33236115Full text
  22. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Yamada Y, Katagiri H, Hamamoto Y, et al. · The lancet. Diabetes & endocrinology · 2020 · Randomised controlled trial DOIPubMed 32333875
  23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40196933Full text
  26. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083
  27. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes care · 2019 · Journal article DOIPubMed 31186300

Ova stranica je automatski prevedena sa engleskog. Citati i brojevi su nepromijenjeni. Pročitajte engleski original ako nešto zvuči čudno. Pročitajte engleski original